Tom focuses on complex litigation, at both the trial and appellate levels, for clients in a wide range of industries. He has successfully tried cases in both state and federal courts, and has guided others through mediation and arbitration. In his appellate practice, Tom has secured victories for clients in the First, Fourth, Ninth, and Federal Circuit Courts of Appeal as well as the Massachusetts Appeals Court.
In matters involving intellectual property, Tom draws on his prior experience as a research chemist. He represents life sciences companies in patent litigation and other intellectual property disputes, and has particular experience representing clients in matters involving pharmaceuticals, biotech, the Hatch-Waxman Act (for small molecule drugs), and the Biologics Price Competition and Innovation Act (for large-molecule biologics).
For education industry clients, Tom draws on his prior experience as a college dean. His clients include colleges and universities, and he represents them in matters as diverse as faculty and student affairs, regulatory compliance (including Title IX), internal investigations, and research misconduct proceedings.
Tom also has significant experience defending class actions in both federal and state courts.
Prior to joining the firm, Tom was a partner in the Boston office of another international law firm, where he was part of the litigation and IP litigation practices and co-chaired the firm's educational institutions practice. Prior to that, he clerked for the Honorable Boyce F. Martin Jr. on the United States Court of Appeals for the Sixth Circuit. Before attending law school, Tom served as Associate Dean of the Faculty at Williams College.
• Mintz Levin Further Expands IP Practice with Eighteen Attorneys, (01.09.2015)
• Featured in Mintz Levin Adds More from Edwards Wildman, Bingham McCutchen, The American Lawyer (01.08.2015)
• Author, Biosimilars, the BPCIA, and Amgen v. Sandoz: The Federal Circuit's First Attempt To Make Sense of “A Riddle Wrapped in a Mystery Inside an Enigma”, Intellectual Property Alert (07.22.2015)
• Author, 2015 Will Be a Watershed Moment for Biosimilars, Law360 (02.03.2015)